WPI 844 (Glipizide extended release 5 mg)
Pill imprint WPI 844 has been identified as Glipizide extended release 5 mg.
Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 5 mg is classified as a Schedule N controlled substance under the Controlled Substance Act (CSA).
- 5 mg
- 6.00 mm
- Prescription only
hydroxyethyl cellulose (2000 mpa.s at 1%)
hydroxypropyl cellulose (type h)
methacrylic acid - methyl methacrylate copolymer (1:1)
FD&C Yellow No. 6
|NDC Code||Manufacturer / Repackager|
|68084-0111||Amerisource Health Services|
|00228-2899||Actavis Pharma, Inc.|
|54569-5547||A-S Medication Solutions, LLC (repackager)|
|54868-5210||Physicians Total Care Inc (repackager)|
|55887-0212||Diversified Healthcare Services Inc (repackager)|
Note: Inactive ingredients may vary.
More about glipizide
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2015 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.